Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis
Peter BB Jones1,2, Douglas HN White21Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 2Rheumatology Department, Waikato Hospital, Hamilton, New ZealandAbstract: Leflunomide is a disease-modifying antirheumatic drug (DMARD) that has been in routine clinical use...
Saved in:
| Main Authors: | Peter BB Jones, Douglas HN White |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2010
|
| Subjects: | |
| Online Access: | https://doaj.org/article/7d7a87290fc4437c8b3c13f26dd4880b |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
by: Fabrizio Cantini, et al.
Published: (2009) -
Optimal management of dactylitis in patients with psoriatic arthritis
by: Yamamoto T
Published: (2015) -
Update on the use of rituximab for intractable rheumatoid arthritis
by: R John Looney
Published: (2009) -
Rheumatoid arthritis: Disease or syndrome?
by: Jessica A Stanich, et al.
Published: (2009) -
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
by: Montepaone M, et al.
Published: (2014)